School of Medicine, Dentistry and Medicine, University of Glasgow, Glasgow, UK.
Department of Radiology, University Hospital Hairmyres, Glasgow, UK.
BJS Open. 2022 May 2;6(3). doi: 10.1093/bjsopen/zrac076.
Phaeochromocytomas are rare tumours with a recurrence after open surgery ranging between 6-23 per cent. Long-term follow-up studies after laparoscopic surgery for phaeochromocytoma are lacking. The aim of this study was to look at the long-term oncological outcome of a consecutive series of patients from a single centre undergoing laparoscopic surgery for a phaeochromocytoma.
Demographic data on all patients with an adrenal tumour or paraganglioma were prospectively kept on a database between September 1999 and December 2017. Electronic hospital records, including imaging from a national linked archiving and communication system, were reviewed for patients with a phaeochromocytoma in November 2021.
During the study interval 135 patients with a phaeochromocytoma were operated on in the unit, of which 118 (87.4 per cent) were attempted laparoscopically. Five (4.2 per cent) were converted to open surgery, whereas 117 had a potentially curative operation. There was no peri- or postoperative mortality. At a median follow-up of 10 (interquartile range 6-12.9) years, only 3 (2.6 per cent) patients died from metastatic phaeochromocytoma. One further patient developed lymph node metastases, which were removed at open surgery. No patient had a local recurrence and the only significant predictor of recurrence was the presence of lymph node metastases (P < 0.001). Two patients developed a contralateral adrenal phaeochromocytoma, while one of these also had a paraganglioma. The Kaplan-Meier estimate of phaeochromocytoma-free survival was 96 per cent (95 per cent c.i. 92.2 to 98.8) at 5 years and 92 per cent (95 per cent c.i. 86.7 to 97.3) at 10 years.
This study demonstrates that long-term oncological outcomes of laparoscopic surgery for patients with a phaeochromocytoma are at least as good as that with an open operation.
嗜铬细胞瘤是一种罕见的肿瘤,开放性手术后的复发率为 6-23%。腹腔镜手术治疗嗜铬细胞瘤的长期随访研究尚缺乏。本研究旨在观察单中心连续系列患者接受腹腔镜手术治疗嗜铬细胞瘤的长期肿瘤学结果。
1999 年 9 月至 2017 年 12 月期间,我们在一个数据库中对所有肾上腺肿瘤或副神经节瘤患者的人口统计学数据进行了前瞻性记录。2021 年 11 月,我们对全国链接归档和通信系统的影像进行了电子病历回顾,以查找嗜铬细胞瘤患者。
在研究期间,该单位共对 135 例嗜铬细胞瘤患者进行了手术,其中 118 例(87.4%)尝试了腹腔镜手术。5 例(4.2%)转为开放性手术,而 117 例进行了潜在的治愈性手术。围手术期无死亡。在中位数为 10 年(四分位距 6-12.9)的随访中,仅 3 例(2.6%)患者死于转移性嗜铬细胞瘤。另有 1 例患者发生淋巴结转移,在开放性手术中切除。无局部复发,唯一显著的复发预测因素是淋巴结转移(P<0.001)。2 例患者发生对侧肾上腺嗜铬细胞瘤,其中 1 例还发生了副神经节瘤。嗜铬细胞瘤无复发生存的 Kaplan-Meier 估计值在 5 年时为 96%(95%置信区间 92.2%至 98.8%),在 10 年时为 92%(95%置信区间 86.7%至 97.3%)。
本研究表明,腹腔镜手术治疗嗜铬细胞瘤的长期肿瘤学结果至少与开放性手术一样好。